• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Janssen Inc. - Articles and news items

Amorsa to collaborate with J&J on treatment-resistant depression therapy

Industry news / 5 January 2017 / Niamh Marriott, Digital Editor

Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression…

guselkumab

EMA to review Janssen’s plaque psoriasis monoclonal antibody

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development…

Price drop means leukaemia CDF drug will be routinely available

Industry news / 2 December 2016 / Niamh Louise Marriott, Digital Editor

Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance…

NICE does not recommend Janssen’s Waldenstrom’s macroglobulinaemia candidate

Industry news / 17 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia…

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

FDA grants breakthrough therapy designation for depression drug

Industry news / 16 August 2016 / Janssen

Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication…

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

NICE asks Janssen to put ibrutinib forward for the CDF

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

NICE has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF)…

Clinical remission data for Stelara in Crohn’s disease presented at DDW

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Data shows that a greater proportion of adult patients with Crohn’s disease receiving Stelara SC maintenance therapy were in clinical remission at one year…

NICE recommends three type 2 diabetes treatments

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin…

Daratumumab combination improves PFS in multiple myeloma study

Industry news / 1 April 2016 / Victoria White

Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone…

Daratumumab and atezolizumab to be evaluated in two studies

Industry news / 22 March 2016 / Victoria White

The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer…

 

Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +